1. IRE1α siRNA relieves endoplasmic reticulum stress-induced apoptosis and alleviates diabetic peripheral neuropathy in vivo and in vitro.
- Author
-
Yao W, Yang X, Zhu J, Gao B, Shi H, and Xu L
- Subjects
- Animals, Cell Line, Diabetic Neuropathies pathology, Disease Models, Animal, Endoribonucleases genetics, Glucose metabolism, Male, Multienzyme Complexes genetics, Protein Serine-Threonine Kinases genetics, Rats, Rats, Sprague-Dawley, Apoptosis, Diabetic Neuropathies therapy, Endoplasmic Reticulum Stress, Endoribonucleases antagonists & inhibitors, Multienzyme Complexes antagonists & inhibitors, Protein Serine-Threonine Kinases antagonists & inhibitors, RNA, Small Interfering therapeutic use, Schwann Cells pathology
- Abstract
Diabetic peripheral neuropathy (DPN) is mainly characterized by demyelination resulted from the apoptosis of the Schwann cell (SCs). Although the exact mechanisms underlying DPN remain unclear, endoplasmic reticulum (ER) stress is strongly implicated in the apoptosis. Under ER stress, activated inositol-requiring kinase 1α (IRE1α) unregulated CHOP, phosphorylated JNK and Caspase-12 to aggravate apoptosis-mediated damage of DPN. Therefore, we tested the hypothesis that inhibition of IRE1α could reduce the ER stress-related apoptosis to relieve DPN. Here, we show that IRE1α siRNA improved the neurological morphology and function of DPN rats and rescued ER stress-related apoptosis in the sciatic nerve. Additionally, RSC96 cells transfected with IRE1α siRNA were used as in vitro model of DPN. It was found that IRE1α siRNA also decreased high glucose-induced apoptosis and inhibited ER stress-related apoptosis in the cells. Altogether, our results suggest that IRE1α should be considered a potential therapeutic agent for DPN.
- Published
- 2018
- Full Text
- View/download PDF